AZ 1729

Key Product Details

Product Description

AZ 1729 is a FFA2 allosteric agonist. Inhibits forskolin-induced cAMP increase and stimulates ³⁵SGTPγS binding in biochemical assays (pEC₅₀ values are 6.9 and 7.23, respectively). Binds at allosteric binding site. In functional assays, displays positive allosteric modulation of FFA-induced G_i signaling and negative allosteric modulation of FFA-induced G_q/G₁₁ signaling. Inhibits lipolytic effect of isoproterenol (pEC₅₀ = 5.03) and induces migration of human neutrophils in vitro.

Product Specifications for AZ 1729

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Solubility

Preparing Stock Solutions for AZ 1729

The following data is based on the product molecular weight 369.42.

Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which all affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:

1 Recalculate

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	2.71 mL	13.53 mL	27.07 mL
5 mM	0.54 mL	2.71 mL	5.41 mL
10 mM	0.27 mL	1.35 mL	2.71 mL
50 mM	0.05 mL	0.27 mL	0.54 mL

Calculators

Background References

References are publications that support the biological activity of the product.

• Sergeev A single extracellular amino acid in free fatty acid receptor 2 defines antagonist species selectivity and G protein selection bias. Sci.Rep. 2017 PMID: 29061999
• Bolognini A novel allosteric activator of free fatty acid 2 receptor displays unique G_i-functional bias. J.Biol.Chem. 2016 PMID: 27385588

Product Documents for AZ 1729